Paris, France, 2 June 2023 - Recently, the EuroPCR 2023, the European Congress of Cardiology, was held in Paris, France, with over 10,000 experts and scholars in attendance. MicroPort Scientific Corporation (MicroPort®) participated in the event with multiple business units and shared the latest clinical research progress of four products: Bioresorbable Coronary Stent, Drug-Eluting Absorbable Coronary Stent System, Left Atrial Appendage Closure Device, and Transcatheter Aortic Valve System. MicroPort® had the honor of showcasing its integrated solutions in the field of cardiovascular intervention.
Doctor Song Lei from Fuwai Hospital, Chinese Academy of Medical Sciences, announced the key findings of the three-year clinical follow-up results of the FUTURE II trial, which focused on Firesorb®, the second-generation fully bioresorbable vascular scaffold system by Shanghai MicroPort® Medical (Group) Co., Ltd. (MicroPort® Coronary). The results showed no significant difference in the three-year target lesion failure rate (4.2% vs. 3.7%, p=0.84) and patient-oriented composite events (13.8% vs. 11.7%, p=0.55) between Firesorb® BRS and the new generation DES. Future studies which include a longer five-year clinical follow-up and a large-scale single-arm OPC study (FUTURE-III, >1000 patients), will provide more clinical evidence for the new generation Firesorb® BRS.
Professor Martin Leon from the New York-Presbyterian Hospital presented the clinical trials roadmap of the TARGET series on the Firehawk® Drug-Eluting Stent system, emphasizing the five-year long-term follow-up of the TARGET All Comers study, which showed target lesion failure (TLF) rates of 17.1% and 16.3% (P=0.68) for the Firehawk® stent treatment group and the control group, respectively. The Firehawk® stent also demonstrated a lower occurrence of late thrombosis, with rates of 1.3% and 1.9% (P=0.20) compared to the control group. Professor Martin Leon stated that several cutting-edge studies including TARGET DAPT, TARGET SAFE, TARGET FIRST, and TARGET IV NA are currently underway in China, Europe, and the United States, and relevant clinical data will be published in the coming year.
In the latest breakthrough clinical trial (LBCT) section of the conference, Professor He Ben from Shanghai Chest Hospital was invited to present the key results of the pre-market clinical study with one-year follow-up for the AnchorMan® Left Atrial Appendage Closure Device, SAFE PROTECT, developed by Shanghai MicroPort CardioAdvent Co., Ltd (MicroPort® CardioAdvent). The study's primary endpoints showed a clinical success rate of 98.1% and a successful occlusion rate of 100% for the left atrial appendage. These results were consistent with the control group. In this study, both groups of patients primarily adopted a combined strategy of atrial fibrillation ablation and left atrial appendage occlusion (AnchorMan® group 73.1%, control group 70.1%), which demonstrated lower rates of device-related thrombus events (DRT), transient ischemic attack (TIA), stroke, major bleeding events, systemic embolism, and all-cause mortality. The study results indicate that the AnchorMan® Left Atrial Appendage Closure Device has shown good clinical effectiveness in clinical practice and is expected to become an important choice for left atrial appendage occlusion treatment in patients with atrial fibrillation.
Professor Tao Ling from Xijing Hospital shared a study on the evaluation of aortic regurgitation in postoperative patients using quantitative aortography with the VitaFlow® Transcatheter Aortic Valve System (VitaFlow®) and other self-expanding transcatheter aortic valve systems. Professor Tao Ling stated that the study showed a lower incidence of moderate to severe aortic regurgitation in patients using VitaFlow® postoperatively.
During the conference, MicroPort® Coronary, CardioFlow Medtech and Hemovent showcased various products to the attendees, including the Firehawk® Drug-Eluting Stent, Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent system, Firefighter™ PTCA Balloon Catheter, VitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System, and MOBYBOX™ Extracorporeal Membrane Oxygenation System. These products attracted a large number of attendees, which engaged information exchanges.
As a leading innovative high-end medical device group, MicroPort® will continue to integrate the expertise and experience of top experts from various countries, collaborate with global doctors who are devoted to patients' well-being, and strive to provide better services to patients and offer more high-quality and accessible integrated solutions for patients worldwide.